November 17, 2026 Ref: NEPHROPLUS/SE/102

To
BSE Limited
P.J. Towers, Dalal Street,
Mumbai - 400 001
Scrip Code: 544647
Through: BSE Listing Centre

To
National Stock Exchange of India Limited
5th Floor, Exchange Plaza, Bandra (E),
Mumbai - 400 051
Scrip Symbol: NEPHROPLUS
Through: NEAPS

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Allotment of Equity Shares pursuant to Exercise of Stock Options under NephroPlus Employees Stock Option Scheme, 2011.

Dear Sir / Madam,

Pursuant to Regulation 30 read with Para A of Part A of Schedule III and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("**SEBI Listing Regulations**"), we hereby inform you that the Nomination and Remuneration Committee ("**NRC**") of the Board of Directors of Nephrocare Health Services Limited ("**the Company**"), by way of a circular resolution passed on November 17, 2026, has approved the allotment of 3,42,130 (Three Lakh Forty-Two Thousand One Hundred Thirty only) equity shares of face value of ₹2/- each, fully paid-up, pursuant to the exercise of stock options by eligible employees under the NephroPlus Employees Stock Option Scheme, 2011 ("**ESOP 2011**"). These equity shares shall rank pari passu with the existing equity shares of the Company in all respects.

Consequent to the aforesaid allotment, the issued, subscribed and paid-up equity share capital of the Company has increased from ₹20,11,18,028, comprising 10,05,59,014 equity shares of face value of ₹2/- each, to ₹20,18,02,288, comprising 10,09,01,144 equity shares of face value of ₹2/- each.

The Company has obtained the in-principle approvals for listing of the aforesaid equity shares from the National Stock Exchange of India Limited vide letter no. NSE/LIST/54518 dated May 11, 2026, and from BSE Limited vide letter no. DCS/ESOP/IP/RD/062/2026-27 dated May 11, 2026.

The disclosures required under Regulation 10(c) of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, are enclosed as **Annexure I**.

Further, the details required under Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, are enclosed as **Annexure II**.

The aforesaid information is also being made available on the Company's website at www.nephroplus.com

Yours faithfully,
For Nephrocare Health Services Limited
(Formerly Nephrocare Health Services Private Limited)

Kathri Kishore
Digitally signed by Kathri Kishore
Date: 2026.11.17 16:28:14 +05'30'

Kishore Kathri
Company Secretary and Head Legal
Membership No.: F9895

Encl: a/a

Annexure I

Sr. No.	Particulars	Remark
1	Company name and address of Registered Office	**Nephrocare Health Services Limited** (Formerly Nephrocare Health Services Private Limited) 5th Floor, D Block, iLabs Centre, Plot 18, Software Units Layout, Survey No. 64, Shaikpet, Hyderabad, 500081
2	Name of the recognized Stock Exchanges on which the company's shares are listed	BSE Limited (BSE) National Stock Exchange of India Limited (NSE)
3	Filing date of the statement referred in regulation 10(b) of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 with the recognized Stock Exchange	April 10, 2026
4	Filing Number, if any	Reference of In-principle Approval a. **NSE -** NSE/LIST/54518 dated May 11, 2026 b. **BSE** - DCS/ESOP/IP/RD/062/2026-27 dated May 11, 2026
5	Title of the Scheme pursuant to which shares are issued, if any	NephroPlus Employees Stock Option Scheme, 2011 ("**ESOP 2011**")
6	Kind of security to be listed	Equity Shares
7	Par value of the shares	₹ 2/- each
8	Date of issue of shares	November 17, 2026
9	Number of shares issued	3,42,130 fully paid-up equity shares of ₹2/- each
10	Share Certificate No., if applicable	Not Applicable
11	Distinctive number of the share, if applicable	10,05,59,015 to 10,09,01,144 (both inclusive)
12	ISIN Number of the shares if issued in Demat	INE428V01029
13	Exercise price per share	Refer **Annexure A**
14	Premium per share	Refer **Annexure A**
15	Total Issued shares after this issue	10,09,01,144
16	Total Issued share capital after this issue	₹ 20,18,02,288
17	Details of any lock-in on the shares	Not Applicable
18	Date of expiry of lock-in	Not Applicable

19	Whether shares identical in all respects to existing shares if not, when will they become identical?	The equity shares allotted shall rank pari passu and are identical in all respects with the existing equity shares including payment of dividend and other rights.
20	Details of listing fees, if payable	Not Applicable

Annexure II

Sr. No.	Particulars	Details
1.	Brief details of options granted	The present instance pertains to the allotment of 3,42,130 equity shares of ₹2/- each, pursuant to the exercise of options under the NephroPlus Employees Stock Option Scheme, 2011 ("**ESOP 2011**").
2.	Whether the scheme is in terms of SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.	Yes
3.	Total number of shares covered by these options	The present instance pertains to the allotment of 3,42,130 equity shares of ₹2/- each, pursuant to the exercise of options under ESOP 2011.
4.	Pricing formula	The Exercise Price payable by an Employee upon exercise of the Options shall be as specified in the respective Grant Letter(s) issued under the ESOP 2011 and shall be payable in accordance with the terms and conditions thereof. For details, please refer **to Annexure A**.
5.	Options vested	The Options exercised in the present instance had vested in accordance with the terms of ESOP 2011 and the respective Grant Letter(s).
6.	Time within which option may be exercised	
7.	Options exercised	Options (as adjusted for the sub-division and bonus issue referred to in Item 9 below) entitling the holders to 3,42,130 equity shares of face value ₹2/- each were exercised for the current allotment.
8.	Money realized by exercise of options	₹5,55,13,127.86 (Rupees Five Crore Fifty-Five Lakh Thirteen Thousand One Hundred Twenty-Seven and Eighty-Six Paise only) excluding applicable taxes
9.	Total number of shares arising as a result of exercise of options	Each stock option granted under the ESOP 2011 originally entitled the option holder, upon exercise, to subscribe to one (1) equity share of the Company having a face value of ₹10/- each. Subsequently, pursuant to the sub-division of every equity share of face value ₹10/- each into five (5) equity shares of face value ₹2/- each, approved by the shareholders of the Company on May 26, 2025, and the subsequent bonus issue in the ratio of 2:1 (i.e., two bonus equity shares for every one equity share

		held), approved by the Board of Directors and the shareholders on the same date, the outstanding stock options were appropriately adjusted in accordance with the provisions of the ESOP 2011 and Regulation 5 of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 ("SEBI SBEB Regulations"), so as to preserve the value of the options and ensure that the employees were neither advantaged nor disadvantaged on account of such corporate actions. Consequently, each original stock option became exercisable into fifteen (15) equity shares of face value ₹2/- each, with the exercise price being correspondingly adjusted in accordance with the adjustment formula prescribed under the ESOP 2011 and the applicable provisions of the SEBI SBEB Regulations. Accordingly, 3,42,130 equity shares of face value ₹2/- each have arisen and been allotted pursuant to the valid exercise of the corresponding adjusted stock options under the ESOP 2011.
10.	Options lapsed	Not Applicable.
11.	Variation of terms of options	Not Applicable.
12.	Brief details of significant terms	Options are granted, vested and exercised in accordance with the provisions of ESOP 2011 and the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The ESOP 2011 is administered by the Nomination and Remuneration Committee of the Board of Directors of the Company. The Options granted under the ESOP 2011 vest over such period and are subject to such time-based, performance-based, business, strategic, market-based and/or other conditions as may be determined by the Nomination and Remuneration Committee at the time of grant and specified in the respective Grant Letter. Vested Options may be exercised within the exercise period specified in the respective Grant Letter.

		The equity shares allotted pursuant to the exercise of vested Options rank pari passu with the existing equity shares of the Company in all respects.
13.	Subsequent changes or cancellation or exercise of such options	Not Applicable
14.	Diluted earnings per share pursuant to issue of equity shares on exercise of options	The diluted earnings per share shall be computed in accordance with the applicable Indian Accounting Standards (Ind AS), particularly Ind AS 33 – Earnings per Share, after giving effect to the allotment of equity shares pursuant to the exercise of Options.

Annexure A

Sr No.	Allotment Date	No. of Equity Shares allotted	Exercise Price (in ₹)	Premium per share (in ₹)	Total Exercise money (in ₹)
1	November 17, 2026	90,000	98.22	96.22	88,39,890.00
2		2,220	78.58	76.58	1,74,440.94
3		3,750	197.33	195.33	7,39,998.75
4		1,500	246.60	244.60	3,69,898.50
5		5,150	197.33	195.33	10,16,264.95
6		5,250	78.60	76.60	4,12,650.00
7		2,250	246.60	244.60	5,54,847.75
8		1,900	176.03	174.03	3,34,447.50
9		36,000	98.22	96.22	35,35,944.00
10		56,880	220.03	218.03	1,25,15,394.00
11		4,140	49.27	47.27	2,03,977.80
12		50,940	220.03	218.03	1,12,08,328.20
13		30,000	197.33	195.33	59,19,900.00
14		11,250	246.60	244.60	27,74,250.00
15		30,000	197.33	195.33	59,19,900.00
16		6,000	78.58	76.58	4,71,460.00
17		1,400	176.03	174.03	2,46,435.47
18		3,500	78.60	76.60	2,75,100.00
Total		**3,42,130**	-		**5,55,13,127.86**

***